Mounjaro (tirzepatide) is FDA-approved to treat type 2 diabetes, and Part D plans cover it widely for that use — typically on a mid-to-higher cost tier with prior authorization to confirm the diagnosis. The exact same molecule is sold as Zepbound for weight management, and there Medicare's statutory exclusion on weight-loss drugs applies, so it's almost never covered. It's the diagnosis, not the drug, that decides it.
Your plan will pay, but only after your prescriber documents that you have type 2 diabetes and, on some plans, that you've tried a first-line drug like metformin first (step therapy). Once approved, Mounjaro sits on Tier 3, so expect a meaningful copay or coinsurance until you reach your plan's catastrophic threshold.
See how Mounjaro — or any drug — lands across all Medicare Part D plans: coverage, tier, and prior authorization.
Look up a drug — freeNo. Mounjaro is approved for diabetes; Medicare can't cover any drug used for weight loss by law. For weight management the equivalent is Zepbound, which is also excluded on nearly all plans.
Both are covered for type 2 diabetes on the large majority of Part D plans (roughly 99%), usually Tier 3 with prior authorization. See Ozempic coverage →
It depends on your plan's Tier 3 cost-share and where you are in the year. Use the lookup to confirm your plan's tier, then check that tier's copay in your plan documents.
Most denials are about the prior-authorization paperwork — a missing diabetes diagnosis or step-therapy history. Making sure your prescriber submits those up front is usually the difference between approval and an appeal.